Clinical trials are currently investigating both monoclonal antibodies and small-molecule agonists designed to target TREM2, with the aim of translating these promising preclinical findings into effective treatments for Alzheimer’s disease. This evidence concerns the gene TREM2 and early-onset autosomal dominant Alzheimer disease.